Gene Network Sciences Awarded Patent Covering REFS(TM) Platform
CAMBRIDGE, Mass., May 4 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has been awarded U.S. Patent No. 7,512,497, entitled "Systems and Methods for Inferring Biological Networks." The patent covers GNS's core model learning and simulation platform, REFS(TM) (Reverse Engineering and Forward Simulation).
GNS has deployed the REFS(TM) platform in several collaborations with pharmaceutical and biotechnology companies and academic and clinical institutions in diseases areas such as oncology, rheumatoid arthritis, cardiovascular and metabolic disease, and Alzheimer's disease. The REFS(TM) platform, which is run on supercomputers, enables the rapid extraction of actionable, patient-specific knowledge directly from experimental and clinical data.
"We have now extended our patent portfolio beyond our previous issued patents covering an ultra-efficient language to model known biology and the simulation of known pathways, to the fully data-driven inference and simulation of novel biology," said Tom Neyarapally, Senior Vice President of Corporate Development for GNS. "GNS now has broad intellectual property coverage across our modeling and simulation activities."
GNS has several other pending patent applications addressing the REFS(TM) platform and its use in areas of application in biological systems and areas outside of biology such as quantitative finance, online advertising, and natural resource exploration, as well as applications covering drug targets, biomarkers, and diagnostic markers discovered using the REFS(TM) platform.
About Gene Network Sciences
Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.
CONTACT: Thomas Neyarapally, +1-617-494-0492 ext. 238
Web site: http://www.gnsbiotech.com//